pirenzepine has been researched along with Affective Disorders in 13 studies
Pirenzepine: An antimuscarinic agent that inhibits gastric secretion at lower doses than are required to affect gastrointestinal motility, salivary, central nervous system, cardiovascular, ocular, and urinary function. It promotes the healing of duodenal ulcers and due to its cytoprotective action is beneficial in the prevention of duodenal ulcer recurrence. It also potentiates the effect of other antiulcer agents such as CIMETIDINE and RANITIDINE. It is generally well tolerated by patients.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We assessed the differences in risk of developing diabetes mellitus during treatment with olanzapine and risperidone by using patients treated with haloperidol and fluphenazine as control subjects in whom we would not expect to see an increased risk." | 7.72 | Comparative study of the development of diabetes mellitus in patients taking risperidone and olanzapine. ( Fuller, MA; Grogg, AL; Secic, M; Shermock, KM, 2003) |
| "We have previously shown a decrease in [(3)H]pirenzepine binding to M1/M4 muscarinic receptors in the anterior cingulate cortex in schizophrenia but not in major depression or bipolar disorder." | 3.73 | M2/M4 muscarinic receptor binding in the anterior cingulate cortex in schizophrenia and mood disorders. ( Huang, XF; Katsifis, A; Yu, Y; Zavitsanou, K, 2005) |
| " We assessed the differences in risk of developing diabetes mellitus during treatment with olanzapine and risperidone by using patients treated with haloperidol and fluphenazine as control subjects in whom we would not expect to see an increased risk." | 3.72 | Comparative study of the development of diabetes mellitus in patients taking risperidone and olanzapine. ( Fuller, MA; Grogg, AL; Secic, M; Shermock, KM, 2003) |
| "The odds of newly reported type 2 diabetes in patients who received risperidone were not significantly different from those in untreated patients (12-month odds ratio [OR] = 1." | 1.32 | Differential effects of antipsychotic agents on the risk of development of type 2 diabetes mellitus in patients with mood disorders. ( Gianfrancesco, F; Grogg, A; Mahmoud, R; Meletiche, D; Wang, RH, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (15.38) | 18.2507 |
| 2000's | 9 (69.23) | 29.6817 |
| 2010's | 2 (15.38) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ztaou, S | 1 |
| Lhost, J | 1 |
| Watabe, I | 1 |
| Torromino, G | 1 |
| Amalric, M | 1 |
| Jeon, WJ | 1 |
| Gibbons, AS | 1 |
| Dean, B | 1 |
| Miller, TJ | 1 |
| Zipursky, RB | 1 |
| Perkins, D | 1 |
| Addington, J | 1 |
| Woods, SW | 1 |
| Hawkins, KA | 1 |
| Hoffman, R | 1 |
| Preda, A | 1 |
| Epstein, I | 1 |
| Addington, D | 1 |
| Lindborg, S | 1 |
| Marquez, E | 1 |
| Tohen, M | 1 |
| Breier, A | 1 |
| McGlashan, TH | 1 |
| Gianfrancesco, F | 1 |
| Grogg, A | 1 |
| Mahmoud, R | 1 |
| Wang, RH | 1 |
| Meletiche, D | 1 |
| Shelton, RC | 1 |
| Bokszanska, A | 1 |
| Martin, G | 1 |
| Vanstraelen, M | 1 |
| Holt, G | 2 |
| Bouras, N | 2 |
| Taylor, D | 1 |
| Fuller, MA | 1 |
| Shermock, KM | 1 |
| Secic, M | 1 |
| Grogg, AL | 1 |
| Zavitsanou, K | 1 |
| Katsifis, A | 1 |
| Yu, Y | 1 |
| Huang, XF | 1 |
| Williams, H | 1 |
| Clarke, R | 1 |
| Martin, J | 1 |
| Iqbal, MM | 1 |
| Gundlapalli, SP | 1 |
| Ryan, WG | 1 |
| Ryals, T | 1 |
| Passman, TE | 1 |
| Buckley, PF | 1 |
5 reviews available for pirenzepine and Affective Disorders
| Article | Year |
|---|---|
The combination of olanzapine and fluoxetine in mood disorders.
Topics: Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Clinical Trials as Topic; Drug Therapy, Com | 2003 |
Atypical antipsychotics for treatment of depression in schizophrenia and affective disorders. Collaborative Working Group on Clinical Trial Evaluations.
Topics: Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Clinical Trials as Topic; Clozapine; Comorb | 1998 |
Treatment of special populations with the atypical antipsychotics. Collaborative Working Group on Clinical Trial Evaluations.
Topics: Adult; Age Factors; Aged; Algorithms; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Clini | 1998 |
Effects of antimanic mood-stabilizing drugs on fetuses, neonates, and nursing infants.
Topics: Abnormalities, Drug-Induced; Acetates; Adult; Amines; Antimanic Agents; Benzodiazepines; Breast Feed | 2001 |
Broad therapeutic uses of atypical antipsychotic medications.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Child; Child Development Disorders, P | 2001 |
2 trials available for pirenzepine and Affective Disorders
| Article | Year |
|---|---|
The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. II. Baseline characteristics of the "prodromal" sample.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Comorbidity; Depressive | 2003 |
Risperidone and olanzapine in adults with intellectual disability: a clinical naturalistic study.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Comorbidity; Di | 2003 |
6 other studies available for pirenzepine and Affective Disorders
| Article | Year |
|---|---|
Striatal cholinergic interneurons regulate cognitive and affective dysfunction in partially dopamine-depleted mice.
Topics: Animals; Cholinergic Neurons; Cognitive Dysfunction; Corpus Striatum; Dopamine; Interneurons; Mice; | 2018 |
The use of a modified [3H]4-DAMP radioligand binding assay with increased selectivity for muscarinic M3 receptor shows that cortical CHRM3 levels are not altered in mood disorders.
Topics: Adult; Aged; Animals; Cerebral Cortex; Dose-Response Relationship, Drug; Humans; Mice; Mice, Knockou | 2013 |
Differential effects of antipsychotic agents on the risk of development of type 2 diabetes mellitus in patients with mood disorders.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Data Collection; Diabetes Mellitus, Type 2; Female; Hu | 2003 |
Comparative study of the development of diabetes mellitus in patients taking risperidone and olanzapine.
Topics: Antipsychotic Agents; Benzodiazepines; Black People; Diabetes Mellitus; Humans; Male; Mood Disorders | 2003 |
M2/M4 muscarinic receptor binding in the anterior cingulate cortex in schizophrenia and mood disorders.
Topics: Adult; Age of Onset; Analysis of Variance; Autoradiography; Brain Mapping; Case-Control Studies; Dos | 2005 |
Use of the atypical antipsychotics Olanzapine and Risperidone in adults with intellectual disability.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Dose-Response Relationship, Drug; Female; Follow-Up St | 2000 |